Department of Otolaryngology & Communication Enhancement, Boston Children's Hospital, Boston, Massachusetts, U.S.A.
Otolaryngology - Head and Neck Surgery, The Hospital for Sick Children, Toronto, Ontario, Canada.
Laryngoscope. 2021 Mar;131(3):E984-E992. doi: 10.1002/lary.28785. Epub 2020 Jul 20.
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. The goal of this research is to analyze the role of surgery in the management of pediatric parameningeal (PM) and non-PM head and neck RMS (HNRMS).
Retrospective review.
Retrospective chart review of patients <20 years of age treated for HNRMS between 1970 and 2015. Clinical presentation, tumor characteristics, treatment, recurrence, follow-up, and outcome data were collected.
Of 97 patients with HNRMS, 56% were male. Overall median (IQR: interquartile range) age at diagnosis was 5.8 (3.3-9.8) years. Sixty-five patients (67%) had PM tumors. Of 75 patients with histologic subtype identified, 51 (53%) had embryonal and 20 (21%) alveolar RMS. Almost all patients received chemotherapy (99%) and radiotherapy (95%). Forty-four patients (45%) underwent surgery. Surgery was more likely to be conducted in patients with lesions of a non-PM site. Median follow-up time was 3.4 years (IQR: 1.1-10.8). In 5 years of follow-up, 20% (17 of 85) died and 29% (20 of 70) had recurrence. The estimated 5-year survival rate was 72% (95% CI, 57.8, 81.5%). Surgery was associated with a reduced risk of mortality after accounting for TNM stage 4 and tumor site (adjusted HR 0.24; 95% CI, 0.07, 0.79; P = .02). The association between surgery and risk of mortality was similar in PM and non-PM tumors.
A multimodal protocol for treatment including chemotherapy, surgery, and radiotherapy is the mainstay for management of children with HNRMS. While surgery is more commonly used to treat non-PM HNRMS, patients who are able to undergo surgery have significantly higher 5-year survival.
4 Laryngoscope, 131:E984-E992, 2021.
横纹肌肉瘤(RMS)是儿童中最常见的软组织肉瘤。本研究旨在分析手术在儿科脑脊膜外(PM)和非 PM 头颈部横纹肌肉瘤(HNRMS)治疗中的作用。
回顾性研究。
回顾性分析 1970 年至 2015 年间治疗 HNRMS 的<20 岁患者的病历。收集临床表现、肿瘤特征、治疗、复发、随访和结局数据。
97 例 HNRMS 患者中,男性占 56%。总体中位(IQR:四分位间距)诊断年龄为 5.8(3.3-9.8)岁。65 例(67%)患者为 PM 肿瘤。75 例患者中,51 例(53%)为胚胎型,20 例(21%)为肺泡型 RMS。几乎所有患者均接受化疗(99%)和放疗(95%)。44 例(45%)患者接受手术。手术更可能在非 PM 部位的病变患者中进行。中位随访时间为 3.4 年(IQR:1.1-10.8)。5 年内,20%(17/85)死亡,29%(20/70)复发。5 年生存率估计为 72%(95%CI:57.8,81.5%)。在考虑到 TNM 分期 4 期和肿瘤部位后,手术与降低死亡率相关(调整后的 HR 0.24;95%CI:0.07,0.79;P=0.02)。手术与死亡率之间的关联在 PM 和非 PM 肿瘤中相似。
包括化疗、手术和放疗在内的多模式治疗方案是儿童 HNRMS 治疗的主要方法。虽然手术更常用于治疗非 PM HNRMS,但能够接受手术的患者 5 年生存率显著提高。
4 级喉镜检查,131:E984-E992,2021 年。